Teva Pharmaceutical Industries (NYSE:TEVA) Insider Mark Sabag Sells 144,180 Shares

Key Points

• Mark Sabag sold 144,180 shares of Teva on May 1 at an average price of $34.99 for about $5.04M, cutting his position by 64.1% to 80,760 shares (he also sold 62,102 shares on March 17 at ~$30.14).
• Teva traded near $35.36 (up ~1.2%) with a 12‑month range of $14.99–$37.35; the company reported $0.53 EPS and $3.98B revenue for the quarter, and analysts forecast roughly 2.6 EPS for the year.
• Analyst sentiment is largely positive—nine Buys versus one Sell—with an average price target of $41.56 and several firms recently raising their targets.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, May 1st. The shares were sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares in the company, valued at $2,825,792.40. The trade was a 64.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Mark Sabag also recently made the following trade(s):

• On Tuesday, March 17th, Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $30.14, for a total value of $1,871,754.28.

Teva Pharmaceutical Industries Trading Up 1.2%

Teva Pharmaceutical Industries stock traded up $0.41 during midday trading on Monday, reaching $35.36. The stock had a trading volume of 7,444,270 shares, compared to its average volume of 8,293,405. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The stock has a market capitalization of $40.65 billion, a PE ratio of 26.58, a price-to-earnings-growth ratio of 3.23 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The stock's 50-day simple moving average is $31.15 and its 200 day simple moving average is $29.46.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The firm had revenue of $3.98 billion for the quarter. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.6 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Phoenix Financial Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock worth $834,164,000 after acquiring an additional 3,533,800 shares in the last quarter. National Pension Service lifted its stake in shares of Teva Pharmaceutical Industries by 24.2% in the third quarter. National Pension Service now owns 2,073,293 shares of the company's stock worth $41,881,000 after acquiring an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board lifted its stake in shares of Teva Pharmaceutical Industries by 11.5% in the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company's stock worth $13,543,000 after acquiring an additional 69,000 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company's stock worth $761,455,000 after acquiring an additional 4,306,363 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in shares of Teva Pharmaceutical Industries by 11.2% in the third quarter. Teacher Retirement System of Texas now owns 697,574 shares of the company's stock worth $14,091,000 after acquiring an additional 69,994 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Barclays lifted their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an "overweight" rating in a report on Friday, January 30th. Truist Financial lifted their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a report on Thursday. Bank of America boosted their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday, April 9th. Wall Street Zen cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "hold" rating in a research note on Saturday. Finally, Scotiabank boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a "sector outperform" rating in a research note on Thursday, January 29th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Teva Pharmaceutical Industries presently has an average rating of "Moderate Buy" and an average target price of $41.56.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.